Myelodysplastic Syndrome: From Diagnosis to Treatment

$230.00

Emma E. Steffensen (Editor)

Series: Recent Advances in Hematology Research
BISAC: MED038000

In this compilation, the authors review the biological aspects of myelodysplastic syndrome disease, diagnosis, and treatment, as well as innovations involving genetics and new treatment perspectives.
Myelodysplastic syndromes are a heterogeneous group of clonal haematopoietic stem cells disorders characterized by dysplasia, as well as peripheral blood cytopenias with a hypercellular marrow and ineffective hematopoiesis.
Myelodysplastic syndromes are frequently associated with acute and chronic inflammation, and autoimmune disorders such as: rheumatoid arthritis, bowel disease, diverse types of vasculitis, autoimmune anemias, several rheumatic and skin disorders, and certain thyroid disorders.
Spliceosome mutations are the most frequent mutations found in blood and bone marrow cells of myelodysplastic syndromes patients. As such, the authors explore the four predominant splicing factor genes: SF3B1, SFRS2, U2AF1, ZRSR2.
Subsequently, this collection discusses the CSNK1A1 gene in the context of myelodysplastic syndromes. It is located at 5q32 within the deleted region, which encodes for casein kinase 1α (CK1α). CK1α is a component of a multiprotein β-catenin destruction complex that regulates Wnt/β-catenin and p53 pathways.
The concluding study focuses on the mutations in epigenetic modifiers occur which myelodysplastic syndromes and drive this disease, such as: DNA methylation, histone acetylation, and RNA interference that alters gene expression.
(Imprint: Nova Medicine and Health)

Clear

Details

Table of Contents

Preface

Chapter 1. Myelodysplastic Syndrome: An Overview
(Lucas Delmonico, Maria Christina Paixão Maioli and Maria Helena Faria Ornellas, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil, and others)

Chapter 2. An Updated Approach to Myelodysplastic Syndromes (MDS)
(Ana Bela Sarmento Ribeiro, Bárbara Marques, Carolina Afonso, Ana Cristina Gonçalves, Nuno Silva, Margarida Coucelo, Paula Laranjeira, Artur Paiva and Emília Cortesão, Laboratory of Oncobiology and Hematology and University Clinic of Hematology/Faculty of Medicine of University of CoimbraS, Coimbra, Portugal, and others)

Chapter 3. The Inflammatory and Autoimmune Dysregulation in Myelodysplastic Syndromes
(Ota Fuchs, Institute of Hematology and Blood Transfusion, Nové Město, Prague, Czech Republic)

Chapter 4. Spliceosome Mutations and Alternative Splicing of Pre-Messenger RNA in Myelodysplastic Syndromes
(Ota Fuchs, Institute of Hematology and Blood Transfusion, Nové Město, Prague, Czech Republic)

Chapter 5. Myelodysplastic Syndrome with Chromosome 5q: Deletion and Its Treatment
(Ota Fuchs, Institute of Hematology and Blood Transfusion, Nové Město, Prague, Czech Republic)

Chapter 6. Epigenetic Mechanisms and Therapy of Myelodysplastic Syndromes
(Ota Fuchs, Institute of Hematology and Blood Transfusion, Nové Město, Prague, Czech Republic)

Index

Additional information

Binding

,